-
1 Comment
Shanghai Medicilon Inc is currently in a long term uptrend where the price is trading 44.0% above its 200 day moving average.
From a valuation standpoint, the stock is 251.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 33.8.
Shanghai Medicilon Inc's total revenue rose by 26.6% to $173M since the same quarter in the previous year.
Its net income has increased by 41.2% to $28M since the same quarter in the previous year.
Finally, its free cash flow grew by 704.9% to $36M since the same quarter in the previous year.
Based on the above factors, Shanghai Medicilon Inc gets an overall score of 4/5.
| ISIN | CNE100003NQ8 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | SHG |
| CurrencyCode | CNY |
| PE Ratio | None |
|---|---|
| Market Cap | 9B |
| Beta | 0.75 |
| Target Price | None |
| Dividend Yield | None |
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates through Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development services; custom and zoom in synthesis; structural, in vitro, and computational biology; protein expression and purification; protein crystallization; and recombinant kinase preparation services, as well as protein target validation, compound activity screening and optimization, raw material and preparation process research, and quality standards and stability research. The company also provides process route screening, API production process optimization, drug process research and application, pharmacology services, drug safety evaluation, biological analysis, IND filing, and TCM preclinical trial service solutions, such as pharmaceutical research, pharmacodynamics, pharmacokinetics, and toxicology. In addition, it provides efficient lipid synthesis, liposome preparation, prescription screening, process optimization and development, quality research, safety evaluation, bioanalysis, registration and declaration, etc.; pre-formulation research, drug analysis, drug stability research, and formulation development; and cytokine and biomarker testing, bioanalysis, and flow cytometry service, as well as assists in the research and development of new drugs. Further, the company is involved in molecular type drug development activities. Shanghai Medicilon Inc. was founded in 2004 and is headquartered in Shanghai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 688202.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
